This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (11)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA

Charles Marwick

JAMA. 1998;279:489-490.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

TWENTY-FIVE YEARS of dogged, often tedious, research into the development of an effective vaccine against a major cause of severe, sometimes lethal diarrhea among children is about to pay off. The Food and Drug Administration (FDA) is expected soon to approve marketing of a vaccine against rotavirus, making it available to pediatricians in the United States. The World Health Organization (WHO) is considering recommending its use in developing countries, where the disease more often has a serious outcome.

The vaccine, which was developed by Albert Z. Kapikian, MD, and colleagues at the Laboratory of Infectious Diseases, part of the National Institute of Allergy and Infectious Diseases (NIAID) in Bethesda, Md, is an unusual technical achievement. It combines a historic principle of immunization, the use of an antigenically related virus to induce protective antibody against another virus—the approach taken by Edward Jenner when he used cowpox to immunize against . . . [Full Text of this Article]

Virtually Universal